InterCure Ltd. Announces 2025 Financial and Operating Results

InterCure Ltd. reported 2025 revenues exceeding NIS 270 million, a 13% increase from 2024. The company experienced a net loss of NIS 37 million, an improvement from NIS 73 million in 2024, attributed to non-cash provisions and war-related impacts. Adjusted EBITDA increased by over 90% to NIS 47 million, marking the twelfth consecutive half-year of positive Adjusted EBITDA. Operating cash flow turned positive at NIS 17 million, a significant turnaround from negative NIS 67 million in 2024. The company also repaid over NIS 35 million in loans. Operational highlights include the resumption of production at the Nir Oz facility, the launch of over 75 new GMP SKUs, and expansion into the German market. Strategic moves include a share purchase agreement to acquire Botanico Ltd. and investment agreements with Cannasoul R&D Ltd. InterCure received NIS 82 million in compensation advances for war-related damages.